LX 9,851 is being developed as a monotherapy and in combination with other drugs. Sonata HCM study aims to enroll 500 patients with results expected by late 2026.
Read MoreDid you find this insightful?
Amazing
Bad
Just Okay
Lexicon Pharmaceuticals Inc (LXRX) Q4 2024 Earnings Call Highlights: Strategic Advances and ...
